News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD

Original Publication Date
Article Source
External Web Content
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with graft-versus-host disease (GVHD), according to a news release from the…

How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji

Original Publication Date
Article Source
External Web Content
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have…

Iron accelerates MDS progression

Original Publication Date
Article Source
External Web Content
In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that iron overload (IOL), accumulated via a mutation in the iron importer ferroportin, accelerates the myelodysplastic syndrome (MDS) phenotype, leading to exacerbation of marrow failure, inferior…

Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial

Original Publication Date
Article Source
External Web Content
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show “robust clinical activity” in patients newly diagnosed with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML)…

State of the Art Treatment in Myelodysplastic Syndromes

Original Publication Date
Article Source
External Web Content
Presenter: Mikkael Sekeres Professor of Medicine, Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine Miami, FL, USA Release Date: December 20, 2024 Congress: ASH 2024 Area: Hematology Description: Mikkael A. Sekeres…

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy

Original Publication Date
Article Source
External Web Content
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe aplastic anemia (SAA). Existing guidance about HCT in SAA is primarily derived from expert reviews, registry data and societal guidelines; however, transplant-specific guidelines…

Therapy for acute myeloid leukemia in older and unfit adults

Original Publication Date
Article Source
External Web Content
TITLE Azacitidine and venetoclax in previously untreated acute myeloid leukemia. AUTHORS DiNardo CD, Jonas BA, Pullarkat V, et al. JOURNAL The New England Journal of Medicine. 2020;383:617-629. doi: 10.1056/NEJMoa2012971. The therapy of acute myeloid leukemia (AML) has…

Can JAK inhibition prevent GVHD?

Original Publication Date
Article Source
External Web Content
In this issue of Blood, Pidala et al report on the results of a multicenter phase 2 trial, in which a graft-versus-host disease (GVHD) prevention regimen of pacritinib, an oral JAK2 inhibitor, in combination with sirolimus and tacrolimus successfully suppressed pSTAT3 signaling…

What have we learned about TP53-mutated acute myeloid leukemia?

Original Publication Date
Article Source
External Web Content
Abstract TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with de novo acute myeloid leukemia (AML), more frequently observed in elderly patients and…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families